Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.35 |
| ▸ | GLP1R | P43220 | 1/20 | 0.35 |
| ▸ | CCR4 | P51679 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5547208 | 0.84 | LOX (0.51) | LOXALDH1A1PTGS2GLP1RCCR4 | |
| SCHEMBL989588 | 0.80 | CYP3A4 (0.50) | CYP3A4TSHRALDH1A1NFE2L2GAA | |
| SCHEMBL7971731 | 0.79 | CYP3A4 (0.41) | CYP3A4TSHRALDH1A1NFE2L2HTR3E | |
| SCHEMBL9179403 | 0.78 | TSHR (0.43) | CYP3A4TSHRALDH1A1NFE2L2GAA | |
| SCHEMBL6501463 | 0.78 | CYP3A4 (0.43) | CYP3A4TSHRALDH1A1NFE2L2 | |
| SCHEMBL30253319 | 0.78 | NOS3 (0.46) | LOXALDH1A1GLP1RCCR4MBOAT4 | |
| SCHEMBL10513207 | 0.78 | CYP3A4 (0.39) | CYP3A4TSHRALDH1A1NFE2L2SMN1; SMN2 | |
| SCHEMBL9174593 | 0.77 | NFE2L2 (0.44) | CYP3A4TSHRALDH1A1NFE2L2PTGS2 | |
| Potassium Ion SCHEMBL9175274 | 0.77 | NFE2L2 (0.44) | CYP3A4TSHRALDH1A1NFE2L2PTGS2 | |
| Lithium Ion SCHEMBL9176164 | 0.77 | NFE2L2 (0.44) | CYP3A4TSHRALDH1A1NFE2L2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564636-B2 | Pnictogen-containing heterocyclic compounds and their use | UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) | 2026-03-03 | — | — | US | disclosed |
| US-20240285772-A1 | PNICTOGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE | COLGATE UNIVERSITY | 2024-08-29 | — | — | US | disclosed |
| EP-3416956-B1 | METHYLAMINE DERIVATIVES AS LYSYL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2024-04-10 | — | — | EP | disclosed |
| WO-2023191953-A1 | PNICTOGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE | UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2023-03-21 | — | — | US | disclosed |
| US-20220372028-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-11-24 | — | — | US | disclosed |
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-05-04 | — | — | US | disclosed |
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-05-04 | — | — | US | disclosed |
| US-20210040078-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-02-11 | — | — | US | disclosed |
| US-20210040078-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-02-11 | — | — | US | disclosed |
| EP-2003116-A9 | PROCESS FOR THE PRODUCTION OF ORGANIC OXIDES | Takeda Pharmaceutical Company Limited (JP) | 2009-05-20 | — | — | EP | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090054655-A1 | Process for the Production of Organic Oxides | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-2003116-A2 | PROCESS FOR THE PRODUCTION OF ORGANIC OXIDES | Takeda Pharmaceutical Company Limited (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1424336-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
| WO-2001017965-A2 | CYANOPIPERIDINES AS PESTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040078-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | CYP3A4 2190/4885TSHR 2329/4885LOX 4/4885 |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | CYP3A4 1744/4885TSHR 1858/4885LOX 2345/4885 |
| US-20220372028-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | CYP3A4 2190/4885TSHR 2329/4885LOX 4/4885 |
| US-20090054655-A1 | Process for the Production of Organic Oxides | OXSR1, CBR3, CYB5R3 | CYP3A4 283/4885TSHR 31/4885LOX 1245/4885 |
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | CYP3A4 2190/4885TSHR 2329/4885LOX 4/4885 |
| US-12564636-B2 | Pnictogen-containing heterocyclic compounds and their use | CBR1, PNPO, NOX3 | CYP3A4 1355/4885TSHR 700/4885LOX 197/4885 |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | MIF, MORF4L1, FOXM1 | CYP3A4 1744/4885TSHR 1858/4885LOX 2345/4885 |
| US-20240285772-A1 | PNICTOGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE | PYGL, UGT2B7, CYP2E1 | CYP3A4 24/4885TSHR 3396/4885LOX 242/4885 |
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | CYP3A4 2190/4885TSHR 2329/4885LOX 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.